DSpace Repository
A narrative review on the effectiveness of tocilizumab in reducing the mortality risk in covid-19 patients
- DSpace Home
- →
- 1. Research Paper
- →
- Journal Articles
- →
- View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.
| dc.contributor.author | Nur Haifa Amani Zulkiply | |
| dc.contributor.author | Vignesh, Ramachandran | |
| dc.contributor.author | Muthukumarasamy, Ravindran | |
| dc.contributor.author | (UniKL RCMP) | |
| dc.date.accessioned | 2022-11-14T04:34:25Z | |
| dc.date.available | 2022-11-14T04:34:25Z | |
| dc.date.issued | 2021-07 | |
| dc.identifier.citation | Nur Haifa Amani Zulkiply, Vignesh, R., & Muthukumarasamy, R. (2021). A Narrative Review on the Effectiveness of Tocilizumab in Reducing the Mortality Risk in COVID-19 Patients. Malaysian Journal of Medicine and Health Sciences, 17(3), 2636–9346. https://medic.upm.edu.my/upload/dokumen/2021062816053138_MJMHS_0854.pdf | en_US |
| dc.identifier.issn | 16758544 | |
| dc.identifier.uri | https://medic.upm.edu.my/jurnal_kami/penerbitan/mjmhs_vol_17_no_3_july_2021-62220 | |
| dc.identifier.uri | http://hdl.handle.net/123456789/26283 | |
| dc.description.abstract | The novel coronavirus disease 2019 (COVID-19) has reached its pandemic scale within a short period of its first case reported in Wuhan, China in December 2019, leading to a great economic crisis all over the world. As of today, there is no clinically approved antiviral drug available for the treatment of COVID-19. Tocilizumab, a humanized monoclonal antibody against the interleukin-6 (IL-6) receptor, clinically approved for the treatment of rheumatoid arthritis, is one such drug used to manage the COVID-19 symptoms. The current study reviews the effectiveness of Tocilizumab as a treatment option for COVID-19. Research findings on Tocilizumab are effective in COVID-19 patients with the risk of cytokine storm and further complications. Nevertheless, this review also recommends further investigation on the effectiveness of this drug with a large group of patients for more accuracy in results with COVID 19 patients | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Universiti Putra Malaysia Press | en_US |
| dc.subject | COVID-19 | en_US |
| dc.subject | Cytokine storm | en_US |
| dc.subject | Interleukin-6 inhibitors | en_US |
| dc.subject | SARS-CoV-2 | en_US |
| dc.subject | Tocilizumab | en_US |
| dc.title | A narrative review on the effectiveness of tocilizumab in reducing the mortality risk in covid-19 patients | en_US |
| dc.type | Article | en_US |
